Nuvation Bio 2024 Investor Presentation - Oncology Pipeline

Nuvation Bio is a late-stage oncology company developing next-generation therapeutics for unmet cancer needs. The company's lead candidate taletrectinib is a best-in-class ROS1 inhibitor completing pivotal studies, while safusidenib targets IDH1-mutant glioma. With a $597 million cash balance, Nuvation Bio is positioned to reach commercial stage in 2025.